Trials / Completed
CompletedNCT05603182
A Study of PRA052 in Healthy Volunteers
A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA052 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA052 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRA052 | PRA052 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2022-11-07
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
- First posted
- 2022-11-02
- Last updated
- 2024-03-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05603182. Inclusion in this directory is not an endorsement.